Efficacy of rituximab in refractory neuromyelitis optica.

Date publication

juin 2016

Journal

Multiple sclerosis (Houndmills, Basingstoke, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26362900

Résumé

Despite a growing use of rituximab (RTX) in neuromyelitis optica (NMO), data are lacking in patients with refractory NMO (RNMO), defined as cases with at least one relapse during immunosuppressive therapy.

Mots clés

Adolescent, Adult, Aged, Body Mass Index, Disability Evaluation, Disease Progression, Female, Humans, Immunosuppressive Agents, adverse effects, Male, Middle Aged, Neuromyelitis Optica, diagnosis, Recurrence, Remission Induction, Risk Factors, Rituximab, adverse effects, Time Factors, Treatment Outcome, Young Adult

Référence

Mult. Scler.. 2016 06;22(7):955-9